Response of treatment-naive brain metastases to stereotactic radiosurgery.

Chibawanye I Ene, Christina Abi Faraj, Thomas H Beckham, Jeffrey S Weinberg, Clark R Andersen, Ali S Haider, Ganesh Rao, Sherise D Ferguson, Christopher A Alvarez-Brenkenridge, Betty Y S Kim, Amy B Heimberger, Ian E McCutcheon, Sujit S Prabhu, Chenyang Michael Wang, Amol J Ghia, Susan L McGovern, Caroline Chung, Mary Frances McAleer, Martin C Tom, Subha Perni, Todd A Swanson, Debra N Yeboa, Tina M Briere, Jason T Huse, Gregory N Fuller, Frederick F Lang, Jing Li, Dima Suki, Raymond E Sawaya
Author Information
  1. Chibawanye I Ene: Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, TX, USA. cene@mdanderson.org. ORCID
  2. Christina Abi Faraj: Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, TX, USA.
  3. Thomas H Beckham: Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA.
  4. Jeffrey S Weinberg: Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, TX, USA. ORCID
  5. Clark R Andersen: Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, TX, USA.
  6. Ali S Haider: Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, TX, USA.
  7. Ganesh Rao: Department of Neurosurgery, Baylor College of Medicine, Houston, TX, USA.
  8. Sherise D Ferguson: Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, TX, USA.
  9. Christopher A Alvarez-Brenkenridge: Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, TX, USA.
  10. Betty Y S Kim: Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, TX, USA. ORCID
  11. Amy B Heimberger: Department of Neurological Surgery, Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. ORCID
  12. Ian E McCutcheon: Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, TX, USA. ORCID
  13. Sujit S Prabhu: Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, TX, USA.
  14. Chenyang Michael Wang: Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA.
  15. Amol J Ghia: Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA.
  16. Susan L McGovern: Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA.
  17. Caroline Chung: Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA.
  18. Mary Frances McAleer: Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA.
  19. Martin C Tom: Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA.
  20. Subha Perni: Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA.
  21. Todd A Swanson: Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA.
  22. Debra N Yeboa: Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA.
  23. Tina M Briere: Department of Radiation Physics, Division of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA.
  24. Jason T Huse: Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA.
  25. Gregory N Fuller: Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA. ORCID
  26. Frederick F Lang: Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, TX, USA. ORCID
  27. Jing Li: Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA.
  28. Dima Suki: Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, TX, USA.
  29. Raymond E Sawaya: Faculty of Medicine and Medical Affairs, American University of Beirut, Beirut, Lebanon.

Abstract

With improvements in survival for patients with metastatic cancer, long-term local control of brain metastases has become an increasingly important clinical priority. While consensus guidelines recommend surgery followed by stereotactic radiosurgery (SRS) for lesions >3 cm, smaller lesions (≤3 cm) treated with SRS alone elicit variable responses. To determine factors influencing this variable response to SRS, we analyzed outcomes of brain metastases ≤3 cm diameter in patients with no prior systemic therapy treated with frame-based single-fraction SRS. Following SRS, 259 out of 1733 (15%) treated lesions demonstrated MRI findings concerning for local treatment failure (LTF), of which 202 /1733 (12%) demonstrated LTF and 54/1733 (3%) had an adverse radiation effect. Multivariate analysis demonstrated tumor size (>1.5 cm) and melanoma histology were associated with higher LTF rates. Our results demonstrate that brain metastases ≤3 cm are not uniformly responsive to SRS and suggest that prospective studies to evaluate the effect of SRS alone or in combination with surgery on brain metastases ≤3 cm matched by tumor size and histology are warranted. These studies will help establish multi-disciplinary treatment guidelines that improve local control while minimizing radiation necrosis during treatment of brain metastasis ≤3 cm.

References

Mol Cancer Ther. 2021 Nov;20(11):2129-2139 [PMID: 34413128]
Radiat Oncol. 2011 May 15;6:48 [PMID: 21575163]
Lancet. 2004 May 22;363(9422):1665-72 [PMID: 15158627]
Front Oncol. 2020 Jul 07;10:781 [PMID: 32733787]
Nat Med. 2018 Dec;24(12):1845-1851 [PMID: 30397353]
Handb Clin Neurol. 2018;149:27-42 [PMID: 29307358]
Nat Rev Cancer. 2020 Jan;20(1):26-41 [PMID: 31601988]
Adv Radiat Oncol. 2019 Jul 26;5(1):43-52 [PMID: 32051889]
J Neurosurg. 2014 Aug;121(2):338-48 [PMID: 24785322]
Cancer Med. 2019 Nov;8(16):6809-6831 [PMID: 31568689]
J Clin Oncol. 2022 Jul 10;40(20):2271-2276 [PMID: 35561283]
Int J Radiat Oncol Biol Phys. 2019 Mar 1;103(3):618-630 [PMID: 30395902]
World Neurosurg. 2021 Jul;151:e839-e856 [PMID: 33974987]
Am J Clin Oncol. 2023 Nov 1;46(11):486-495 [PMID: 37580873]
J Neurooncol. 2010 Jan;96(1):45-68 [PMID: 19960227]
J Neurosurg. 2019 Feb 15;132(2):512-517 [PMID: 30771783]
J Neurosurg. 2015 Aug;123(2):373-86 [PMID: 25978710]
Lancet Oncol. 2009 Nov;10(11):1037-44 [PMID: 19801201]
J Clin Oncol. 2022 Feb 10;40(5):492-516 [PMID: 34932393]
Eur Radiol. 2021 Jun;31(6):4114-4129 [PMID: 33241519]
Oncotarget. 2016 Mar 15;7(11):12318-30 [PMID: 26848525]
Int J Mol Sci. 2020 Dec 07;21(23): [PMID: 33297519]
Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1142-8 [PMID: 27209508]
Neuro Oncol. 2019 Feb 14;21(2):242-251 [PMID: 30265328]
Curr Opin Oncol. 2021 Nov 1;33(6):597-607 [PMID: 34534142]
J Neurosurg. 2018 May 4;130(3):804-811 [PMID: 29726782]
J Neurooncol. 2017 Jul;133(3):595-602 [PMID: 28500560]
Int J Radiat Biol. 2019 Jul;95(7):936-939 [PMID: 31120369]
Lancet Oncol. 2017 Aug;18(8):1040-1048 [PMID: 28687375]
J Clin Oncol. 2011 Jan 10;29(2):134-41 [PMID: 21041710]
Lancet Oncol. 2017 Aug;18(8):1049-1060 [PMID: 28687377]
Neuro Oncol. 2020 May 15;22(5):639-651 [PMID: 31793634]
BMC Cancer. 2023 Mar 25;23(1):273 [PMID: 36964529]
Neurosurgery. 2003 Aug;53(2):272-80; discussion 280-1 [PMID: 12925241]
Pract Radiat Oncol. 2022 Jul-Aug;12(4):265-282 [PMID: 35534352]
Med Phys. 2021 Apr;48(4):2038-2049 [PMID: 33590493]
J Neurooncol. 2015 Oct;125(1):149-56 [PMID: 26307446]

MeSH Term

Radiosurgery
Humans
Brain Neoplasms
Male
Female
Middle Aged
Aged
Magnetic Resonance Imaging
Melanoma
Adult
Treatment Outcome
Tumor Burden
Aged, 80 and over
Treatment Failure
Retrospective Studies